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Recent experimentation conducted in our laboratory described the generation of B 
cell hybridomas whose antibody product neutralized interleukin 2  (IL-2)  (formerly 
called T  cell growth factor) -dependent T  cell replication (1). Three discrete experi- 
mental  arguments  suggested  that  the  inhibitory  activity  was  associated  with  a 
monoclonal  IgG  antibody  directed  against  IL-2  determinants.  First,  passage  and 
subsequent  acid elution of cloned hybrid cell culture supernate over a  protein  A- 
Sepharose  column  yielded  purified  IgG  fractions  that  inhibited  mouse,  rat,  and 
human  IL-2  activity. Second, hybridoma-derived IgG in concert  with lyopholized 
Staphylococcus aureus (Igsorb) was capable of precipitating both "cold" and biosynthet- 
ically radiolabeled IL-2 activity. Finally, Sepharose conjugated with purified anti- 
IL-2 IgG provided an extremely active IL-2 absorbtion matrix (1). 
Given the hypothesized role that IL-2 plays in mitogen-induced T cell proliferation 
(2)  and in the antigen-driven differentiation of cytolytic effector cells (3), we asked 
whether monoclonal antibody directed against IL-2 would have a  suppressive effect 
on either (a) mitogen-stimulated T cell proliferation or (b) antigen-directed generation 
of alloreactive cytolytic T cells (CTL). In this communication, we report that addition 
of monoclonal anti-IL-2 IgG to cultures of concanavalin A  (Con A)-stimulated or 
alloantigen-activated murine splenocytes inhibited both mitogen-induced prolifera- 
tion  and  the  in  vitro  generation of CTL.  Furthermore,  the  capacity of anti-IL-2 
antibody to inhibit T  cell proliferation was enhanced by the presence of insolubilized 
S.  aureus. These results support the contention that IL-2 production is obligatory for 
T  cell mitogenesis and the in vitro generation of alloreactive CTL, and furthermore 
suggest that antibodies to IL-2 may prove to be of significant value as immunosup- 
pressive agents. 
Materials and Methods 
Production and Purification of Monoclonal Anti-IL-2 IgG.  Spleen cells harvested  from BALB/e 
mice previously immunized with rat IL-2 were fused with the drug-marked myeloma SP-2. 
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Several of the resultant hypoxanthine-aminopterin-thymidine-resistant  hybrid cell clones se- 
creted a soluble product that significantly inhibited (>50%) IL-2-dependent T cell proliferation 
when  tested in conventional T  cell growth factor microassays (4).  Of the potential anti-IL-2 
secreting hybridomas, the clone designated 4E 12B2H5 was selected for further characterization 
based on the capacity of this cell line's supernate to totally inhibit IL-2-dependent T  cell line 
proliferation. In fact, when tested at a  dilution of 1:20 in the presence of the co-precipitating 
matrix Igsorb (The Enzyme Center, Boston, Mass.), 4E 12B2H5 culture supernate completely 
abrogated tritiated thymidine ([3H]TdR) incorporation of T  cell lines as monitored after 24-h 
culture in the presence of 3 U/ml IL-2 (1). 
Peritoneal ascites containing large concentrations of anti-IL-2 antibody were produced by 
intraperitoneal challenge of BALB/c female mice (6-8 wk of age, from the Central Animal 
Facility, Fred Hutchinson Cancer Research Center) with 2 X  106 4E12B2H5  hybridoma cells. 
Mice  were  challenged  1 wk  after  intraperitoneal  injection with  0.5  ml  of pristane  (Baker 
Chemical Co., Seattle, Wash.). 10-14 d after the administration of4E12B2H5 hybridoma cells, 
intraperitoneal ascites were harvested, clarified by centrifugation, and  frozen  (-20°C)  until 
used for purification of anti-IL-2 IgG. 
IgG purification was achieved by successive binding/elution from protein A-coupled Seph- 
arose (Pharmacia Fine Chemicals, Piscataway, N. J.). 3-5 ml of hybridoma ascites was passed 
over  a  10-ml  protein A-Sepharose column  equilibrated  in  0.9%  NaCI.  Anti-IL-2 IgG  was 
removed from the column by elution with 200 mM glyeine HC1 buffer, pH 3. Purified antibody 
was then dialyzed overnight against 1,000 vol of 0.9% NaCI Hepes, pH 7.2, and frozen (-20°C) 
until use. The approximate antibody concentration was determined by absorbtion of ultraviolet 
light  (280  nm)  using a  Beckman spectrophotometer (Beckman Instruments,  Inc.,  Fullerton, 
Calif.),  E~s~ =  10.  The  capacity of the  antibody  to  inhibit  IL-2-dependent  T  cell  line 
proliferation was assayed in 200 #1 cultures containing 4 x  104 IL-2-dependent T  cell line cells 
(CTLL-2)  (5),  3 U/ml IL-2, and various concentrations of anti-IL-2 IgG. Replicate cultures 
(precipitating) also contained Igsorb at a final dilution of 1:200. Inhibition of proliferation was 
assessed  by  a  4-h  pulse  of [3H]TdR  (20  Ci/mM,  New  England  Nuclear,  Boston,  Mass.). 
[3H]TdR incorporation was assessed by liquid scintillation. 
Mitogenesis Assays.  The effect of anti-IL-2 on T cell mitogen-induced proliferation was tested 
in replicate 200 #1 cultures (RPMI 1640, 2% fetal calf serum [FCS], 50 U/ml penicillin, 50 #g/ 
ml  streptomycin, and  300 #g/ml  fresh  L-glutamine) of C57BL/6  splenocytes (106 cells/ml) 
containing 2 #g/ml Con A  and various concentrations of anti-IL-2 IgG in the presence and 
absence of Igsorb (final dilution of 1:400).  As a  further control, separate Con A  stimulation 
cultures were initiated that contained an identical concentration of a  monoclonal anti-gpT0 
antibody of the same IgG subclass. The latter was generously provided by Dr. R. C. Nowinski 
and  Dr.  Milton Tamm  of the  Tumor  Virology Program  of the  Fred  Hutchinson  Cancer 
Research Center. 
Mixed Lymphocyte Culture (MLC) Generation of Alloreactive CTL.  The effect of anti-IL-2 on 
the generation of CTL was tested in 2 ml MLC  (RPMI  1640,  2%  FCS) containing 5  X  106 
C57BL/6 responder spleen cells and 10  ~ BALB/e irradiated (1,500 rad) splenic stimulator cells. 
Replicate MLC were conducted containing varying concentrations of either anti-IL-2 IgG or 
an irrelevant monoclonal IgG in the presence and/or absence of Igsorb (1:400 final dilution). 
After 5 d of culture (37°C in a humidified atmosphere of 5% CO2 in air), viable effector cells 
were harvested and tested for their ability to lyse 51Cr-labeled allogeneic (H-2  a)  P815 masto- 
cytoma target cells. Methods for performance of 4-h 51Cr release assays in 200 #1 V-bottomed 
microculture  wells  have  been  described  in  detail elsewhere  (6).  Percent  specific lysis was 
determined by using the following equation: 
cpm liberated in effector cell cultures 
-  cpm liberated in background release culture  percent specific lysis =  100 × 
cpm liberated in detergent lysis culture 
-  cpm liberated in background release culture 
Results 
Anti-IL-2 Inhibiton of T Cell Line Proliferation.  Fig. 1 reviews the ability of 4E 12B2H5 
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F16.  1.  [aH]TdR incorporation mediated by 4,000 CTLL-2 cells during hours 20-24 of culture in 
200 #1 volumes, containing 3 U/ml IL-2. Various hybridoma or control supernates and purified IgG 
were tested for the ability to inhibit IL-2  dependent T  cell  proliferation in the presence (11) or 
absence (~)  of Igsorb  (1:200 final  dilution).  Control-conditioned media  (CM)  and  hybridoma 
supernates were tested at  a  final dilution of 1:20 by volume,  Purified IgG was assayed  at  the 
concentrations indicated. 
[aH]TdR incorporation of CTLL-2 ceils. In the absence of anti-IL-2 or in the presence 
of parent  myeloma SP-2  cell-conditioned  medium, CTLL-2  cells  cultured  in  the 
presence of 3 U/ml IL-2 (with or without Igsorb) incorporated maximal amounts of 
[3H]TdR  during  a  4-h  pulse  some  20  h  after culture  initiation.  However,  in  the 
presence of a  1:20 dilution of crude 4E12B2H5 hybridoma culture supernate, IL-2- 
induced [3H]TdR incorporation was markedly inhibited. Similar levels of inhibition 
were observed in CTLL-2 cell cultures containing IL-2 and 4E12B2H5 hybridoma- 
derived IgG (purified by protein-A Sepharose affinity chromatography). Greater than 
90% inhibition of proliferation was observed in cultures containing either 10 or 1 ptg/ 
ml of4E12B2H5 IgG, whereas 10/~g/ml of anti-gp70 IgG in identical cultures had no 
effect on IL-2-driven CTLL-2 cell replication. 
Monoclonal Anti-IL-2 IgG Inhibition of T  Cell Mitogenesis.  Given (a)  the capacity of 
monoclonal 4E12B2H5  antibody to  inhibit  IL-2-dependent T  cell proliferation in 
both  neutralizing and  precipitating  (in  concert  with  Igsorb)  cultures  and  (b)  the 
hypothesis  that  IL-2  is  the  driving  force  behind  normal  mitogen-induced T  cell 
proliferation (2, 7, 8), we were curious to determine what effect anti-IL-2 IgG would 
have on Con A-induced T  cell mitogenesis. As shown in Table I, inclusion of anti-IL- 
2 IgG in cultures of Con A-stimulated normal murine spleen cells severely inhibited 
resultant T  cell proliferation as assessed by [3H]TdR incorporation during hours 72- 
76 in culture. Significant inhibition was observed with <1 ~g/ml of 4E12B2H5 IgG. 
However, Con A  stimulation conducted either in the absence of anti-IL-2 or in the 
presence of 20 #g/ml of anti-gp70 IgG resulted in splenoeyte stimulation indices >25 
times the background [3H]TdR incorporation observed. 
As  was  repeatedly  seen  in  assays  testing  the  effect  of anti-IL-2  on  T  cell  line 
proliferation, the ability of anti-IL-2 IgG to inhibit mitogenesis was dose-dependent 
and enhanced in Igsorb-containing cultures. The capacity of the Igsorb reagent to 
augment inhibition of mitogenesis parallels our previous observation using anti-IL-2 
to inhibit the proliferation of an IL-2-dependent T  cell line (1). Collectively consid- 
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TABLE I 
Effects of Anti-IL-2 on Con A-induced Spleen Cell Mitogenesis 
[3H]Tdr incor- 
Responder cells  Con A  Antibody  Igsorb  poration cpm 
(1:400)  hours 72  76* 
2 tag/ml 
C57BL/6  -  --  -  6,142 
C57BL/6  +  --  -  85,180 
C57BL/6  +  Anti-IL-2 (5 gg/ml)  -  4,163 
C57BL/6  +  Anti-IL-2 (2/Lg/ml)  -  5,965 
C57BL/6  +  Anti-IL-2 (1 pg/ml)  -  16,199 
C57BL/6  +  Anti-gp70 (20/xg/ml)  -  78,165 
C57BL/6  -  --  +  3,065 
C57BL/6  +  --  +  76,168 
C57BL/6  +  Anti-IL-2  (5 ~g/ml)  +  2,965 
C57BL/6  +  Anti-IL-2  (2 #g/ml)  +  1,938 
C157BL/6  +  Anti-II-2 (1/~g/ml)  +  4,937 
C157BL/6  +  Anti-IL-2 (0.5 #g/ml)  +  19,996 
C57BL/6  +  Anti-gp70  (20 #g/ml)  +  83,795 
* Values  given are  the  mean of four replicate  cultures.  Standard  deviation  values were 
consistently <  10%. 
with reactivity directed against  determinants distal to the biologically active site of 
the lymphokine. 
Effect of Anti-IL-2 on the MLC Generation of Alloreactive  CTL.  Based on the ability of 
anti-IL-2  IgG to inhibit  T  cell mitogenesis,  we  asked  whether similar  addition  of 
4E12B2H5  hybridoma  antibody  to  MLC  would  result  in  decreased  generation 
of cytolytic  effector cell  reactivity.  As  detailed  in  Fig.  2,  addition  of anti-IL-2 
(at  concentrations  as  low  as  1 /.tg/ml)  at  the  initiation  of alloantigen-stimulated 
C57BL/6 spleen cell cultures markedly inhibited resultant effector cell reactivity as 
monitored 5  d  later in  4-hour SlCr release assays.  As  was  observed in  mitogenesis 
experimentation, the ability of anti-IL-2 to inhibit MLC-driven CTL differentiation 
was dose-dependent and was more effective in cultures conducted in the presence of 
a co-precipitating matrix (Fig. 2; Table II). 
The data displayed in Table II also detail the deleterious effect that  addition of 
4E12B2H5 IgG had on the recovery of viable effector cells from MLC. Therefore, not 
only did anti-IL-2 serve to depress the lytic activity of CTL generated in MLC, but 
also significantly curtailed proliferation and recovery of responsive T  cells. In contrast 
to  the  results  obtained  when  cultures  were supplemented  with  anti-IL-2  IgG,  the 
addition  of an  irrelevant  anti-gp70  immunoglobulin  had  no  effect  on  the  lytic 
reactivity of alloreactive CTL generated (even when tested at antibody concentrations 
as high as 40 ~g/ml) or on viable cell recovery (Table II). 
Discussion 
The  results  presented  in  this  communication  have  detailed  the  capacity  of a 
monoclonal IgG antibody directed against a determinant present on IL-2 to severely 
inhibit several proliferation-dependent in vitro T  cell immune responses. In addition 
to curtailing II-2-dependent T  cell line proliferation, the addition of the 4E12B2H5 
IgG reagent  to spleen celt cultures markedly inhibited both Con A-induced T  cell 
mitogenesis  and  alloantigen-indueed  generation  of CTL.  The  ability  of anti-IL-2 
monoclonal antibody to inhibit these responses provides strong serological evidence 
that the production and use of IL-2 is essential for mitogen-induced T cell proliferation GILLIS, GILLIS, AND HENNEY 
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FIc;.  2.  Viable effector cells harvested from 5-day MLC  (C57BL/6 spleen cells stimulated  in vitro 
with x-irradiated BALB/c splenocytes) were tested for lytic reactivity against 51Cr-labeled P815 (H- 
2 d)  tumor target  cells.  Responses  detailed  are those of effeetor  cells harvested  from  control  MLC, 
(O), MLC  containing either  1 (&) or 5  (R) #g/ml  of protein-A-Sepharose-purified  anti-IL-2 IgG. 
TABLE II 
Effect of Anti-IL-2 on MLC Generation of Alloreactive CTL (Igsorb 
Precipitation 1:400 Final Dilution) 
Percent  X-irradiated  effector cells  Anti IL-2 present  yield 
Percent specific lysis 
(P815) 
50:1  25:1  10:1 
C57BL/6 ×  BALB/c  None  38  58  54  45 
C57BL/6 X BALB/c  10 #g/ml  4  0  0  0 
C57BL/6 ×  BALB/c  5 #g/ml  11  0  0  0 
C57BL/6 ×  BALB/c  2 p.g/ml  13  25  17  8 
C57BL/6 ×  BALB/c  1 p.g/ml  29  33  25  16 
C57BL/6 ×  BALB/c  0.5 #g/ml  33  38  28  16 
effector cells  Anti-gp70 
present 
C57BL/6 ×  BALB/c  None  47  60  47  39 
C57BL/6 ×  BALB/c  40 #g/ml  44  59  40  32 
C57BL/6 ×  BALB/c  20 #g/ml  52  54  38  32 
G57BL/6 x  BALB/c  l0 #g/ml  51  58  46  32 
C57BL/6 ×  BALB/c  5 #g/ml  45  59  42  35 
C57BL/6 ×  BALB/c  2 ~g/ml  53  58  41  31 
5-d MLC, 50:1 responder:stimulator  ratio. 
and for the in vitro differentiation of alloreactive CTL. The dose-dependent ability of 
anti-IL-2  IgG  to  inhibit  CTL  generation  when  assessed  both  in  terms  of resultant 
MLC  cell  recovery  and/or lytic  activity  provides  suggestive  evidence  that IL-2  not 
only  drives  the  replication  of  antigen-primed  effector  cells  but  influences  CTL 
differentiation as well. 
Taken together with previous studies, which showed that only ligand-activated T 
cells could either absorb IL-2 or proliferate  in response  to in vitro stimulation with 
purified IL-2 (2, 7), the ability of antibody against IL-2 to inhibit T  cell mitogenesis 
and the in vitro generation of alloreactive CTL argues forcibly in favor of the pivotal 
role  that  IL-2  plays  in  controlling T  cell  proliferation.  In  fact,  it  seems  clear  that 
antigen-dependent  IL-2  production  and  use  is  what  fuels  ligand-activated  T  cell 
proliferation responses rather than the lectin or antigen itself. 
Based  on the data  presented  above,  it  would appear  that  in addition  to being a 
potentially useful reagent for IL-2 radioimmunoassays and affinity purification of IL- 
2,  anti-IL-2  IgG  may  be  of importance  in  dissecting  the  involvement  of IL-2  in  a 
number of disease  states,  most  notably hyperimmune  syndromes  and T  cell  malig- 988  GILLIS, GILLIS, AND HENNEY  BRIEF  DEFINITIVE REPORT 
nancy. In this regard it is interesting to note that the coupling of fluorescein to anti- 
IL-2 monoclonal antibody has resulted  in  the generation  of an interesting  reagent, 
which,  when  tested  in  cytoplasmic fluorescence assays, specifically stains  only IL-2 
producer cells (S. Gillis and D. Stull, unpublished observations). Finally, as indicated 
by  its  capacity  to  dramatically  dampen  mitogen-induced  T  cell  replication  and 
alloantigen-triggered CTL responses, it is conceivable that antibody directed against 
determinants present  on the IL-2 molecule may function  as an immunosuppressive 
drug. Such a reagent may be of value if indeed antigen-induced IL-2 production is a 
feature in aggravating hyperimmune disorders. 
Summary 
Our recent studies  have detailed  the generation of B  cell hybridomas whose IgG 
product significantly inhibits interleukin 2 (IL-2)-dependent T  cell replication. Given 
the capacity of such hybridoma antibody to interfere with the activity of mouse, rat, 
and human IL-2, we asked whether anti-IL-2 IgG would mediate similar inhibitory 
effects on other  in vitro immune responses.  In  this communication,  we report  that 
addition of purified anti-IL-2 monoelonal antibody to either mitogen- or alloantigen- 
stimulated spleen cells exerted markedly deleterious effects on both resultant  T  cell 
proliferation  and  the  generation  of cytolytic  effector  cells.  These  results  provide 
serological  evidence  in  support  of the  integral  role  that  IL-2  plays  in  controlling 
antigen/mitogen-induced T  cell proliferation and serves further to define the ability 
of monoclonal antibody against IL-2 to function as an immunosuppressive agent. 
Received  for publication 26 May 1981. 
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